⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
XNCR News
Xencor, Inc.
Form 8-K
sec.gov
XNCR
Marengo Nominates First Drug Candidate Under Strategic TriSTAR Collaboration with Ipsen and Welcomes Industry-Leading T-Cell Engager Expert, Saso Cemerski, Ph.D., to Accelerate Pipeline Expansion
prnewswire.com
AZN
BIIB
XNCR
Form 8-K
sec.gov
XNCR
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
businesswire.com
XNCR
Xencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty Matter
businesswire.com
XNCR
A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs
prnewswire.com
GTBP
XNCR
CTMX
ZYME
NRIX
Form 8-K
sec.gov
XNCR
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
globenewswire.com
NVS
TLX
PFE
EXEL
LLY
XNCR
BTE
ORIC
MRK
ABBV
BMY
AZN
AMGN
SCANBO® FEATURED IN GOVERNMENT OF BRITISH COLUMBIA'S 2026 LIFE SCIENCES ECOSYSTEM MAP
prnewswire.com
ABCL
STEM
XNCR
Bi/Multispecific Drugs in Oncology Analytical Tool Featuring Top Developers - Amgen, Hoffmann-La Roche, J&J, Xencor, Biocytogen - Unlocking New Precision, Immune Activation, and Therapeutic Potential
globenewswire.com
AMGN
JNJ
XNCR